What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

Health Policy

Volumn 44, Issue 3, 1998, Pages 253-260

  Schneeweiss, Sebastian ^a,b   Schöffski, Oliver ^d   Selke, Gisbert W ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c Wissenschaftliches Institut der AOK WIdO   (Germany)

^d NONE

Author keywords

Adverse health outcomes; Drug reimbursement policy; Evaluation; Reference based drug pricing; Substitution

Indexed keywords

ARTICLE; BUDGET; COST CONTROL; DRUG COST; GERMANY; HEALTH CARE POLICY; REIMBURSEMENT;

CANADA; COST SHARING; DRUG COSTS; DRUG THERAPY; GERMANY; HEALTH CARE REFORM; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PHARMACEUTICAL SERVICES; PROGRAM EVALUATION; RATE SETTING AND REVIEW; THERAPEUTIC EQUIVALENCY;

EID: 0032104786     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(98)00023-2     Document Type: Article

References (29)

1. Ministry of Health. New prescription drug policy to save money and protect Pharmacare. Press release, Ministry of Health and Ministry Responsible for Seniors. British Columbia, 10th November 1995.
2. Redwood H The Dynamics of Drug Pricing and Reimbursement in the European Community. 1992;Oldwicks Press, Felixstowe.
3. British Columbia Pharmacy Association. Position Statement, Reference-based Pricing. British Columbia Pharmacy Association, Richmond, 1996.
4. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Journal of Cardiology. 13:1997;33-38.
5. McLaughlin PR Reference-based pricing of prescription drugs. Canadian Journal of Cardiology. 13:1997;31-32.
6. Boulet AP, Tessier G Reference-based pricing in British Columbia: Implications for cardiologists - an analysis. Canadian Journal of Cardiology. 13:1997;46-51.
7. Litsch M, Reichelt H, Selke GW. Auswirkungen der Arzneimittelfestbeträge [Effects of Reference Based Pricing]. Bonn: WIdO, 1990.
8. Reichelt H, Selke GW. Auswirkungen der Arzneimittelfestbeträge [Effects of Reference Based Pricing]. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs - Report '90. Stuttgart, 1990.
9. Reichelt H, Selke GW. Auswirkungen der Arzneimittelfestbeträge [Effects of Reference Based Pricing]. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs - Report '91. Stuttgart, 1991.
10. Selke GW. Auswirkungen der Arzneimittelfestbeträge [Effects of Reference Based Pricing]. In: Schwabe U, Paffrath D, editor. Arzneiverordnungs - Report '92. Stuttgart, 1992.
11. Rothman K Modern Epidemiology. 1986;Little Brown, Boston.
12. Campbell DT Reforms as experiments. American Psychologist. 43:1969;409-429.
13. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine. 331:1994;650-655.
14. Liang K-Y, Zeger SL Regression analysis for correlated data. Annual Review of Public Health. 14:1993;43-68.
15. Lewis MA, Meyer R, Döpfmer S, Guggenmoos-Holzmann I Rapid Response Unit [Möglichkeiten und Bedarf der Pharmakoepidemiologie in Deutschland]. 1997;Verbund Klinische Pharmakologie, Berlin/Brandenburg.
16. Lewis MA Establishing rapid response capability: a German approach. Pharmacoepidemiology Drug Safety. 6:1997;37-40.
17. Schöffski O Consequences of implementing a drug budget for office based physicians in Germany. Pharmacoeconomics. 10(Suppl 2):1996;37-47.
18. Graf Schulenburg JM Management of cost and utilization of pharmaceuticals in Germany. Health Policy. 41:1997;S45-53.
19. Himmel W, Kron M, Thies-Zajoncs, Kochen MM Changes in drug prescribing under the public health reform law - a survey of general practitioners' attitudes in East and West Germany. International Journal of Clinical and Pharmaceutical Therapy. 35:1997;164-168.
20. Katz EM Pharmaceutical spending and German reunification: Parity comes quickly to Berlin. Health Care Financing Review. 15:1994;141-156.
21. Ljungkvist MO, Andersson D, Gummarsson B Cost and utilization of pharmaceuticals in Sweden. Health Policy. 41:1997;55-69.
22. Abel-Smith B, Mossialos E Cost containment and health care reform: a study of the European Union. Health Policy. 28:1994;89-132.
23. de Vos CM The 1996 pricing and reimbursement policy in The Netherlands. Pharmacoeconomics. 10(Suppl 2):1996;75-80.
24. Rigter H Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement. Pharmacoeconomics. 6(Suppl 1):1994;15-21.
25. Gross DJ, Ratner J, Perez J, Glavin SL International pharmaceutical spending controls: France, Germany, Sweden and the United Kingdom. Health Care Financing Review. 15:1994;127-140.
26. Kane NM Pharmaceutical cost containment and innovation in the United States. Health Policy. 41:1997;S71-89.
27. Walser BL, Ross-Degnan D, Soumerai S Do open formularies increase access to clinically useful drugs? Health Affairs. 15:1996;95-109.
28. Kane NM, Saltman RB Comparative experience in home care and phamaceutical policy. Health Policy. 41:1997;S1-7.
29. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J A critical analysis of studies of state drug reimbursement policies: Research in need of discipline. Milbank Quarterly. 71:1993;217-252.